^
    Back
    Association details:
    Biomarker:ROS1 fusion + NBN mutation
    Cancer:Lung Adenocarcinoma
    Drug:Tyvyt (sintilimab) (PD1 inhibitor) +
    Zejula (niraparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Ann Transl Med
    Title:

    A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report

    Excerpt:
    ...he was diagnosed with lung adenocarcinoma (LUAD). Next generation sequencing (NGS) revealed that he harbors ROS1 fusion and NBN germline mutation….the patient was switched to sintilimab combined with niraparib and the efficacy was evaluated as stable disease (SD), with a progression-free survival (PFS) of more than 12 months, and the overall survival (OS) is 23 months up to now.
    DOI:
    10.21037/atm-22-3582